Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results from the Phase 2 TULIP‐LN Trial
Objectives Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon (IFN) signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in pati…